hepatitis a vaccine inactivated (Rx) - Havrix, Vaqta
Adult Dosing & Uses
Dosing Forms & Strengths
injection
- 25 units/0.5 mL
- 50 units/mL
- 720 ELISA units/0.5mL
- 1440 ELISA units/mL
Active immunization against hepatitis A virus
Havrix
- 1 mL IM, repeat at 6-12 mth
Vaqta
- 1 mL IM, repeat at 6-18 mth
Additional Information
Up-to-date vaccination schedules available at www.cdc.gov/nip/publications
Other Indications & Uses
Active immunization against hepatitis A virus
Behavioral occupational hazards:
- IV drug use; multiple sex partners
- Working w/ Hepatitis A virus
Pediatric Dosing & Uses
Dosing Forms & Strengths
injection
- 25 units/0.5 mL
- 50 units/mL
- 720 ELISA units/0.5mL
- 1440 ELISA units/mL
Active immunization against hepatitis A virus
Havrix
- >12 mo: 0.5 mL IM, repeat at 6-12 mth
Vaqta
- >12 mo: 0.5 mL IM, repeat at 6-18 mth
Drug Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Adverse Effects
Suspected adverse events after administration of any vaccine may be reported to Vaccine Adverse Events Reporting System (VAERS), 1-800-822-7967
>10%
Injection site tenderness (3-56%), erythema (1-22%), warmth (1-17%), swelling (9-11%)
Irritability (11-36%)
Anorexia (1-19%)
Drowsiness (15-17%)
Headache (1-16%)
Fever > 100.4 F (9-11%)
1-10%
URI (1-10%)
Otitis media (8%)
Rhinorrhea (6%)
Diarrhea (1-6%)
Cough (1-5%)
Rash (1-5%)
Weakness/fatigue (4%)
Vomiting (1-4%)
Fever > 102 F (3%)
Crying (2%)
<1%
Hematoma
Incr. CPK
Photophobia
Vertigo
Contraindications & Cautions
Contraindications
Documented hypersensitivity
Cautions
First dose at least 2 wk before exposure to HAV
Current exposure to HAV: may co-administer IG
Pregnancy & Lactation
Pregnancy Category: C
Lactation: not established
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Pharmacology
Mechanism of Action
Attenuated strain of hepatitis A virus (HAV) which stimulates active immunity
Onset: 4 wk
Duration: unknown
These products convey active immunity via stimulation of production of endogenously produced antibodies
The onset of protection from disease is relatively slow, but duration is long lasting (years)
